NICE recommends Rinvoq for adults with active psoriatic arthritis

CompilationFan Dongdong

AbbVie's 15mg dose of Rinvoq (upadacitinib) is recommended for the treatment of adults with active psoriatic arthritis (PsA), according to the UK's National Institute for Health and Care Excellence (NICE) recently released a final assessment decision (FAD).
New selection
.

UK NICE recommends upadacitinib alone, or upadacitinib in combination with methotrexate, for the treatment of patients with poor response or intolerance to anti-rheumatic drugs (DMARDs)

Following approval by NICE in the UK, AbbVie's Rinvoq (upadacitinib) is now covered by NHS care in the UK for the treatment of adult patients with active psoriatic arthritis who meet the appropriate conditions
.

According to AbbVie, only if the patient has peripheral arthritis with three or more tender joints and three or more swollen ligaments and is ineligible for two conventional antirheumatic drugs and at least one biological Treatment with upadacitinib will only be considered when anti-rheumatic drugs or TNF-α inhibitors are used

The decision to recommend this recommendation is primarily based on data from the Phase III SELECT-PsA1 (NCT03104400) and SELECT-PsA2 (NCT03104374) clinical trials
.

Two trials evaluated the efficacy, safety and tolerability of Rinvoq in patients with PsA

The most common adverse events reported with the oral 15 mg dose of Rinvoq during the 24-week placebo-controlled period were upper respiratory tract infection and increased blood creatine phosphokinase
.

The frequency of herpes zoster and herpes simplex with the oral 15 mg dose of Rinvoq was 1.

In addition, AbbVie just announced a week ago that it has submitted new indication applications for Rinvoq to regulators in the U.
S.
and Europe for the treatment of radiology-negative axial spondyloarthritis (nr-axSpA)
.

In addition to nr-axSpA, the FDA announced on Friday an expanded indication of AbbVie's Rinvoq (upadacitinib) for the treatment of moderate-to-severe atopic dermatitis in adults or children 12 years of age and older -- patients with previous Not responding to treatment, and the condition cannot be controlled with other treatments, or other treatments are not appropriate

At present, AbbVie is trying to slow down the performance impact of its blockbuster Humira biosimilar when it hits the U.
S.
market in 2023 by vigorously developing Rinvoq and another rookie in immunology, Skyrizi
.

The two drugs have also made impressive progress in 2021, with Rinvoq's global sales of $453 million in the third quarter of 2021 and Skyrizi's third-quarter sales of $796 million

Reference source: NICE recommends Rinvoq® for adults with active psoriatic arthritis